TY - JOUR
T1 - Management of children and adolescents with bronchiectasis
T2 - Summary of the ERS clinical practice guideline
AU - Chang, Anne B.
AU - Grimwood, Keith
AU - Boyd, Jeanette
AU - Fortescue, Rebecca
AU - Powell, Zena
AU - Kantar, Ahmad
N1 - Funding Information:
A.B. Chang reports grants from the National Health and Medical Research Council (NHMRC), Australia, for various project grants and a Centre of Research Excellence relating to various aspects of bronchiectasis in children, as well as an NHMRC Practitioner fellowship (1058213), during the conduct of the study; and fees paid to her institution from GSK (Independent Data Monitoring Committee (IDMC) member for an unlicensed vaccine), Merck (advisory member of study design for an unlicensed molecule for chronic cough), and Moderna (IDMC member for a COVID-19 vaccine for children), outside the submitted work. K. Grimwood reports grants from the National Health and Medical Research Council (NHMRC), Australia, for various project grants and a Centre of Research Excellence relating to various aspects of bronchiectasis in children, during the conduct of the study. J. Boyd is an employee of the European Lung Foundation. R. Fortescue has nothing to disclose. Z. Powell has nothing to disclose. A. Kantar has nothing to disclose.
Publisher Copyright:
© 2021, European Respiratory Society. All rights reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Bronchiectasis, characterised by chronic wet/productive cough with recurrent respiratory exacerbations and abnormal bronchial dilatation on computed tomography scans, remains an increasingly recognised but often neglected chronic pulmonary disorder in children and adolescents. An early diagnosis combined with optimal management offers the prospect, at least in some patients, of curing a condition previously considered irreversible. However, unlike in adults, until now no international paediatric guidelines existed. The recently published European Respiratory Society clinical practice guidelines for the management of children and adolescents with bronchiectasis attempts to address this clinical information gap. The guidelines were formulated by panel members comprised of experts from several relevant health fields, the European Lung Foundation and parents of children with bronchiectasis. Systematic reviews and the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach guided the nature and strength of recommendations. The recommendations are grouped into clinically relevant topics: diagnosis, evaluating for underlying causes, defining exacerbations, management, systematic care, monitoring, reversibility and prevention. The guidelines seek to achieve: 1) optimal lung growth, 2) preserved lung function, 3) enhanced quality of life, 4) minimal exacerbations, 5) few or no complications, and 6) if possible, reversal of lung injury for each child/adolescent with bronchiectasis. This review presents example cases that highlight the recommendations of the clinical practice guidelines.
AB - Bronchiectasis, characterised by chronic wet/productive cough with recurrent respiratory exacerbations and abnormal bronchial dilatation on computed tomography scans, remains an increasingly recognised but often neglected chronic pulmonary disorder in children and adolescents. An early diagnosis combined with optimal management offers the prospect, at least in some patients, of curing a condition previously considered irreversible. However, unlike in adults, until now no international paediatric guidelines existed. The recently published European Respiratory Society clinical practice guidelines for the management of children and adolescents with bronchiectasis attempts to address this clinical information gap. The guidelines were formulated by panel members comprised of experts from several relevant health fields, the European Lung Foundation and parents of children with bronchiectasis. Systematic reviews and the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach guided the nature and strength of recommendations. The recommendations are grouped into clinically relevant topics: diagnosis, evaluating for underlying causes, defining exacerbations, management, systematic care, monitoring, reversibility and prevention. The guidelines seek to achieve: 1) optimal lung growth, 2) preserved lung function, 3) enhanced quality of life, 4) minimal exacerbations, 5) few or no complications, and 6) if possible, reversal of lung injury for each child/adolescent with bronchiectasis. This review presents example cases that highlight the recommendations of the clinical practice guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85118920134&partnerID=8YFLogxK
U2 - 10.1183/20734735.0105-2021
DO - 10.1183/20734735.0105-2021
M3 - Review article
C2 - 35035559
AN - SCOPUS:85118920134
SN - 1810-6838
VL - 17
JO - Breathe
JF - Breathe
IS - 3
M1 - 210105
ER -